We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

JNJ’s stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.

According to TipRanks.com, Sulewski is a 4-star analyst with an average return of 8.0% and a 48.5% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Collegium ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the ...

Pfizer PFE recently announced a landmark deal with the Trump administration. Per the deal, Pfizer committed to key measures aimed at lowering prescription drug costs while boosting investment in ...

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion. PFE is ...